Chardan lowered the firm’s price target on Immuneering to $16 from $21 and keeps a Buy rating on the shares after the company reported topline data from the Phase 1 portion of its study of lead MEK inhibitor candidate IMM-1-104. The data show clean safety and affirm pathway inhibition in line with preclinical modeling, but are not yet showing a clear signal of single agent activity in this late line patient population, says the firm, which is updating its model to reflect a “slightly more conservative” view of the odds of success in pancreatic cancer and non-small cell lung cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMRX:
- Immuneering Appoints New Director, Advances Cancer Drug Trial
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Immuneering appoints Thomas Schall to board of directors
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Immuneering doses first patient in Phase 2a trial of IMM-1-104
